Regeneron Pharmaceuticals (REGN) stock news

Regeneron Pharmaceuticals (REGN) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-10-30 15:06:58 UTC#546545duplicateconfirmednews

Regeneron Q3 revenue up 36% and non-GAAP EPS up 70% on record sales for Dupixent, Eylea HD, and Libtayo

quartrimportance 0.30trust 0.70Regeneron Pharmaceuticals, Inc. +0.60Dupixent +0.60Eylea HD +0.60+1 entities

2026-10-30 12:29:17 UTC#545608duplicateconfirmednews

Regeneron Q3 revenue $5.1B and non-GAAP EPS $20.07, supported by Dupixent and Libtayo growth

quartrimportance 0.30trust 0.70Regeneron Pharmaceuticals, Inc. +0.50Sanofi S.A. +0.40Dupixent +0.40+1 entities

2026-10-30 11:09:18 UTC#544938duplicateconfirmednews

Regeneron Q3 2026 earnings beat expectations on 36% YoY revenue growth

seeking alphaimportance 0.30trust 0.70Regeneron Pharmaceuticals, Inc. +0.60Sanofi S.A. +0.40

2026-10-30 10:53:00 UTC#544755duplicateconfirmednews

Regeneron Q3 2026 Revenue $5.1B, Non-GAAP EPS $20.07; Announces Sanofi Collaboration and FDA Approval of Pasatru

tradingviewimportance 0.40trust 0.80Regeneron Pharmaceuticals, Inc. +0.60Sanofi S.A. +0.30Pasatru +0.50+1 entities

2026-10-30 10:50:00 UTC#544783duplicateconfirmednews

Sanofi CEO reiterates M&A focus for pipeline growth following FY26 guidance upgrade

dow_jonesimportance 0.30trust 0.90Sanofi +0.60Regeneron Pharmaceuticals, Inc. +0.30Dupixent +0.60

2026-10-30 10:32:19 UTC#544643updateconfirmeddata release

Regeneron Pharmaceuticals Q3 2026 Non-GAAP EPS $20.07 beats by $3.82, Revenue $5.1B beats by $540M

seeking alphaimportance 0.70trust 0.90Regeneron Pharmaceuticals, Inc. +0.80

2026-10-30 10:30:00 UTC#544590updateconfirmeddata release

Regeneron Pharmaceuticals reports Q3 2026 revenue of $5.12 billion

dow_jonesimportance 0.50trust 0.90Regeneron Pharmaceuticals, Inc. +0.30

2026-10-30 10:30:00 UTC#544589updateconfirmeddata release

Regeneron Pharmaceuticals reports Q3 2026 net income of $1.95 billion

dow_jonesimportance 0.40trust 0.90Regeneron Pharmaceuticals, Inc. 0

2026-10-30 10:30:00 UTC#544583newconfirmeddata release

Regeneron Pharmaceuticals reports Q3 2026 EPS of $18.45

dow_jonesimportance 0.60trust 0.90Regeneron Pharmaceuticals, Inc. 0

2026-10-30 08:18:00 UTC#543817duplicateconfirmedanalysis

J.P. Morgan sees 3-5% consensus forecast upgrades for Sanofi following Q3 earnings beat

dow_jonesimportance 0.30trust 0.80Sanofi S.A. +0.60JPMorgan Chase & Co. +0.20Regeneron Pharmaceuticals, Inc. +0.30+1 entities

2026-10-30 07:22:00 UTC#543535duplicateconfirmednews

Sanofi raises FY26 outlook on Dupixent strength, signals M&A to address pipeline gaps

dow_jonesimportance 0.30trust 0.80Sanofi S.A. +0.40Regeneron Pharmaceuticals, Inc. +0.30Dupixent +0.40

2026-10-28 22:45:00 UTC#533185newconfirmednews

Canaccord Genuity raises Regeneron Pharmaceuticals price target to $922 from $875, maintains Buy

dow_jonesimportance 0.30trust 0.70Regeneron Pharmaceuticals, Inc. +0.30Canaccord Genuity Group Inc. +0.30

2026-10-27 15:43:07 UTC#522496duplicateconfirmednews

Kiniksa Pharmaceuticals shares rise following Q3 earnings beat and strong Arcalyst performance

seeking alphaimportance 0.30trust 0.60Kiniksa Pharmaceuticals, Ltd. +0.60Regeneron Pharmaceuticals, Inc. +0.40Arcalyst +0.60

2026-10-26 11:53:43 UTC#514427duplicateconfirmednews

Regeneron extends US government supply agreement for Ebola treatment Inmazeb

reutersimportance 0.30trust 0.90Regeneron Pharmaceuticals, Inc. +0.30United States Department of Health and Human Services +0.20Inmazeb +0.30

2026-10-26 11:50:50 UTC#514355newconfirmednews

Regeneron secures $270M US government contract to supply Inmazeb through 2031

reutersimportance 0.40trust 0.90Regeneron Pharmaceuticals, Inc. +0.30Biomedical Advanced Research and Development Authority +0.30Inmazeb +0.20+2 entities

2026-10-26 11:50:00 UTC#514360duplicateconfirmednews

Regeneron secures $270 million US government contract extension for Ebola treatment Inmazeb through 2031

dow_jonesimportance 0.40trust 0.90Regeneron Pharmaceuticals, Inc. +0.40Biomedical Advanced Research and Development Authority +0.30Inmazeb +0.40+1 entities

2026-10-25 09:17:53 UTC#511030newconfirmednews

Regeneron reports Libtayo achieves 37% reduction in risk of death at 44 months in clinical trial

reutersimportance 0.50trust 0.90Regeneron Pharmaceuticals, Inc. +0.60Libtayo +0.60

2026-10-25 09:15:00 UTC#511035duplicateconfirmednews

Regeneron reports 4-year C-POST trial data showing 37% reduced risk of death for Libtayo in high-risk CSCC

tradingviewimportance 0.40trust 0.70Regeneron Pharmaceuticals, Inc. +0.50Libtayo +0.50C-POST +0.40

2026-10-25 09:15:00 UTC#511034duplicateconfirmedpress release

Regeneron reports 4-year follow-up data for Libtayo in Phase 3 C-POST trial for CSCC

globenewswireimportance 0.40trust 1.00Regeneron Pharmaceuticals, Inc. +0.60Libtayo +0.60European Society for Medical Oncology 0+1 entities

2026-10-23 11:00:00 UTC#506256newforecastnews

Regeneron Pharmaceuticals Q3 2026 earnings preview: Analysts expect $4.56B revenue and $16.37 EPS

tradingviewimportance 0.40trust 0.60Regeneron Pharmaceuticals, Inc. 0